Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

Market Cap	6.46B
Revenue (ttm)	1.22B
Net Income (ttm)	-348.16M
Shares Out	2.06B
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,212,800
Average Volume	79,603,189
Open	3.120
Previous Close	3.120
Day's Range	3.020 - 3.150
52-Week Range	2.030 - 3.880
Beta	0.35
RSI	65.60
Earnings Date	Apr 23, 2025

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company’s finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,497
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300267

Financial Performance

In 2024, SHE:300267's revenue was 1.14 billion, a decrease of -36.09% compared to the previous year's 1.78 billion. Losses were -373.37 million, 91.2% more than in 2023.